Back

Myocardial work and exercise LVEF as predictors of impaired cardiorespiratory fitness in breast cancer patients

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in cardiovascular disease in special populations (2) Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Margarida Castro

Hospital Guimaraes, Guimaraes (Portugal)

6 More presentations in this session

Presentation thumbnail
The heart is just one part: body fat as a predictor of impaired cardiorespiratory fitness in breast cancer patients
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Effect of anthracycline chemotherapy on biomarkers and their relation to cardiorespiratory fitness
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Vascular 18F-FDG uptake in breast cancer patients: a marker of vascular disease and its implications for cardiovascular risk
Doctor R. Fernandes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Ascending thoracic aorta 18F-FDG PET-CT uptake in hypertensive breast cancer patients: a marker for vascular disease?
Doctor R. Fernandes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Cancer therapies and atrial fibrillation: examining incidence, risk factors, and clinical implications for patients
Doctor S. Esteves (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in cardiovascular disease in special populations (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Is cancer therapy-related cardiac dysfunction associated to functional disability in breast cancer patients treated with anthracyclines?
thumbnail
Congress Presentation
Effect of anthracycline chemotherapy on biomarkers and their relation to cardiorespiratory fitness
thumbnail
Congress Presentation
The breast cancer chemotherapy influence negatively exercise tolerance assessed in CPET three months after treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources